CRI IGNITE Award 2027: Up to $1.05 Million Across Five Years to Carry a Cancer Immunology Postdoc Through to a Tenure-Track Lab of Their Own

CRI IGNITE Award 2027: Up to $1.05 Million Across Five Years to Carry a Cancer Immunology Postdoc Through to a Tenure-Track Lab of Their Own

Most funding for early-career scientists stops exactly where the risk starts. A postdoctoral fellowship pays for the bench years, and a mid-career award picks you up once you already have a lab, a department, and a track record. In between sits the transition — the job search, the negotiation over start-up funds, the first eighteen months in a new department when nobody is paying you to fail. That gap is where a lot of promising immunology careers quietly end.

The Cancer Research Institute’s IGNITE Award — Inspiring Growth and Nurturing Independence Through Excellence — is built specifically to span it. It commits up to $1.05 million to a single researcher across five years, structured in two sequential phases: a Foundation Phase of up to two years at $150,000 per year while you are still a postdoc, and an Independence Phase of up to three years at $250,000 per year once you have accepted a tenure-track assistant professorship. The money follows the person, not the position.

The next application deadline is 11 January 2027 at 11:59 p.m. Eastern Time. Applicants are notified of committee decisions within roughly 10 to 12 weeks.

Key Details at a Glance

What the Award Actually Pays For

The two phases are deliberately different in character, and understanding the difference matters for how you write the application.

Phase 1, the Foundation Phase, runs up to two years at $150,000 annually. Of that, $90,000 a year is salary support and $60,000 a year funds independent work. That second number is the point of the phase. It is not a top-up to your mentor’s project — it is seed money for a research direction that you will carry with you out of the lab. A postdoc who spends the Foundation Phase generating preliminary data for a line of work their mentor will keep after they leave has misread the award.

Phase 2, the Independence Phase, runs up to three years at $250,000 annually and begins once you have accepted a tenure-track assistant professor position. Phase 2 is not automatic: it requires that you completed at least 12 months of Phase 1, that you have a genuine tenure-track offer, and — critically — that your hiring institution provides an adequate start-up package. CRI is explicit that during Phase 2 the awardee must have at least 65 percent effort available for research, including the CRI-funded project.

That 65 percent effort floor, along with the start-up package requirement, is the structural teeth of the award. CRI is not willing to be the sole funder of a new lab, and it does not want its money absorbed into a department that will bury the awardee in teaching and service. The award is framed as a co-investment: CRI brings the money, the institution brings lab space, protected research time, mentorship, and a real start-up package.

Who This Fits — and Who It Doesn’t

The eligibility rules for Phase 1 are tight and worth reading against your own situation before you invest weeks in an application.

You must be in a mentored postdoctoral position at the time of application, with no more than five years of postdoctoral experience (CRI notes that exceptions are available, which typically means career interruptions are considered rather than that the limit is soft). You must not currently hold — and must never have held — an independent research faculty or tenure-track faculty position or its equivalent. And you must be able to commit to a minimum of 12 months of mentored research before transitioning.

That last requirement rules out a specific and fairly common candidate: the senior postdoc who already has a faculty offer in hand and is looking for money to bring with them. If you are starting your lab in nine months, IGNITE is not the right instrument. The program is designed for someone roughly one to three years out from the job market, who intends to use the Foundation Phase to build the independent research program they will be hired on.

On the permissive side, there is no citizenship requirement, and research may be conducted in the United States or abroad. This is genuinely open internationally, which is not true of most U.S. career-transition awards. A postdoc in a European, Asian, African, or Latin American lab working on tumour immunology is as eligible as one at a U.S. cancer centre.

The scientific scope is CRI’s standing focus: immunology and cancer immunotherapy. CRI’s mission language is about advancing discovery and accelerating the development of immunotherapies. Work that is immunological but has no plausible line of sight to cancer, or oncology work with no real immunology in it, is a poor fit regardless of quality.

Where IGNITE Sits Among CRI’s Other Programs

CRI runs a ladder of programs, and choosing the right rung is part of applying well:

• CRI Irvington Postdoctoral Fellowship — $243,000, for early-career postdocs in immunology and cancer research. Deadlines 1 September 2026 and 1 March 2027.
• CRI Immuno-Informatics Postdoctoral Fellowship — $243,000, for postdocs combining immunology with data science. Same deadlines.
• CRI IGNITE Award — $1.05M, for the postdoc-to-faculty transition. Deadline 11 January 2027.
• CRI Lloyd J. Old STAR Program — $1.25M, for mid-career investigators pursuing high-risk, high-reward work. Deadline 15 January 2027.
• CRI Technology Impact Award — $600,000. Letter of intent due 16 November 2026.
• CRI Clinic and Laboratory Integration Program — $300,000. Letter of intent due 1 December 2026.
• CRI Clinical Innovator — $1M. Deadline 1 December 2026.

If you are early in a postdoc and not yet thinking about the job market, an Irvington or Immuno-Informatics fellowship is the better target — and a strong Irvington record is exactly the kind of history that makes a later IGNITE application credible. If you already run a lab, IGNITE is closed to you and STAR is the relevant program.

What You Have to Submit

The application is substantial, and much of it depends on other people, which is the part applicants underestimate.

From you, the candidate:

• CV and bibliography
• A statement of background and accomplishments
• Publication history — one to three publications with a description of the significance of each
• A narrative on career goals and objectives
• A career development plan for the award period

Items two through five are capped at roughly 500 words each. That is a real constraint. You are not writing a dissertation on your own promise; you are writing four tight, distinct arguments. A common failure is that all four end up saying the same thing in different registers.

From your mentor and referees:

• A mentor letter of support that includes a supervision plan and a transition strategy
• Co-mentor letters, if applicable
• Mentor biosketches
• Documentation of current research support
• Two recommendation letters from people who are not your mentor

The mentor letter is doing unusual work here. It is not only vouching for you — it must lay out how the mentor will supervise you during Phase 1 and how they will help you leave. A mentor letter that reads as though the writer expects to keep you and your project indefinitely undermines the application, however glowing it is.

Research plan:

• Project title, lay summary, and technical summary
• Specific aims
• A research plan of two to three pages spanning both phases
• A detailed budget for Years 1–2

Additional materials at the Phase 2 transition:

• An updated budget for Years 3–5
• A final progress report from the mentored phase
• A commitment letter from the departmental chair
• The official job offer letter for the tenure-track position
• An updated research plan and specific aims

Applications are submitted through CRI’s SmartSimple portal at https://cri.us-1.smartsimple.com/s_Login.jsp.

How to Prepare a Competitive Application

Write one research plan, not two. The two-to-three page plan must span both phases. The strongest versions read as a single scientific argument with a natural hinge: here is what I can establish with my mentor’s reagents, models, and expertise; here is the question that opens up, which I will pursue in my own lab. Weak versions read as a postdoc project stapled to a wish list. Reviewers are assessing whether the Phase 1 work genuinely sets up the Phase 2 work, because that is the whole thesis of the award.

Be explicit about what is yours. Because the award is about independence, the reviewers need to know which ideas, models, tools, and collaborations you will be able to take with you. If a central reagent or model belongs to your mentor’s lab, say so and say how the transfer will work. Ambiguity here is read as a risk, not as modesty.

Brief your mentor properly. Give them the requirement in writing: the letter needs a supervision plan and a transition strategy. Tell them the review committee is looking for evidence that they will actively help you leave. Most mentors will write a better letter if they understand what the award is trying to do; very few will infer it.

Choose publications for the argument, not the impact factor. You get one to three publications with a description of significance for each. Pick the ones that build the case that you can drive a project — first-author work where your contribution is legible — and use the significance descriptions to explain what the work changed, not where it appeared.

Think about the institutional side early. Phase 2 depends on a start-up package and 65 percent research effort. You will not have an offer at application time, but you should understand that when the offer comes, IGNITE gives you leverage in the negotiation — and also a constraint you must protect. Knowing this in January 2027 will make you a better negotiator eighteen months later.

Give the referees time. Two non-mentor letters, mentor and co-mentor letters, and mentor biosketches all have to land before the deadline. Aim to have requests out by early December 2026 at the latest.

Common Mistakes

• Applying with a faculty offer already in hand. The 12-month mentored-research minimum makes this ineligible, and applicants sometimes discover it late.
• Treating the $60,000 independent-work line as supplementary lab funds. It is the mechanism by which you become independent. Budget it as such.
• A Phase 2 plan that could only be executed in the mentor’s lab. If the second half of the plan depends on infrastructure, cohorts, or collaborators that will not travel with you, the plan is not a plan for independence.
• Blowing the word limits. Roughly 500 words each for four narrative items is a discipline. Overlong or repetitive submissions signal that you have not thought hard about what distinguishes each question.
• Immunology without cancer, or cancer without immunology. CRI funds the intersection. Excellent work outside it will not be rescued by its excellence.
• Assuming international applicants are disadvantaged. There is no citizenship requirement and research may be conducted abroad. Do not self-select out.

Frequently Asked Questions

When is the deadline? 11 January 2027, 11:59 p.m. Eastern Time.

When will I hear back? Applicants are notified of committee decisions within approximately 10 to 12 weeks of the deadline — so roughly late March to early April 2027.

Can I apply from outside the United States? Yes. There is no citizenship requirement, and research may be conducted in the United States or abroad.

How much postdoctoral experience is too much? No more than five years at the time of application. CRI notes exceptions are available; if you have had a career interruption, contact CRI rather than assuming you are ineligible.

Is Phase 2 guaranteed if I get Phase 1? No. Phase 2 requires completion of at least 12 months of Phase 1, an accepted tenure-track assistant professor position, and an adequate institutional start-up package, with at least 65 percent effort available for research.

What if I do not find a faculty position during Phase 1? The Foundation Phase is capped at two years. The award is structured around a transition happening within that window, so the timeline should shape how aggressively you plan your job search.

Can I hold another award at the same time? CRI maintains an FAQ page covering concurrent support and related questions; check it against your specific situation before applying, and contact CRI directly if the answer is not clear.

Timeline to Work Backwards From

• August–September 2026 — Decide whether IGNITE or an Irvington/Immuno-Informatics fellowship is the right target. Note the 1 September 2026 fellowship deadline if you pivot.
• October 2026 — Draft the two-phase research plan. This is the long pole; everything else is assembled around it.
• Early December 2026 — Request mentor letter, co-mentor letters, biosketches, and two non-mentor recommendations. Send your mentor the supervision-plan and transition-strategy requirement in writing.
• Late December 2026 — Finalise narratives against the ~500-word limits; complete the Years 1–2 budget.
• Early January 2027 — Submit through SmartSimple well ahead of the 11 January cutoff. Portal congestion on deadline day is a self-inflicted risk.
• Late March–April 2027 — Decisions expected.

Official Links and Contact

• Program page: https://www.cancerresearch.org/ignite
• All CRI grant programs: https://www.cancerresearch.org/apply-for-grants
• CRI programs FAQ: https://www.cancerresearch.org/programs-faqs
• Application portal: https://cri.us-1.smartsimple.com/s_Login.jsp

Cancer Research Institute 29 Broadway, Floor 4 New York, NY 10006-3111

Verify all dates, amounts, and eligibility details on the official CRI page before applying, as program terms can be revised between cycles.